Capital Counsel’s Gilead Sciences GILD Stock Holding History

Capital Counsel’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.61M	Sell	68,928 -282	-0.4%	-$39.5K	0.41%	17
2025 Q4	$8.49M	Hold	69,210	–	–	0.32%	18
2025 Q3	$7.68M	Hold	69,210	–	–	0.29%	18
2025 Q2	$7.67M	Buy	69,210 +1,058	+2%	+$113K	0.31%	17
2025 Q1	$7.64M	Hold	68,152	–	–	0.34%	17
2024 Q4	$6.3M	Sell	68,152 -1,158	-2%	-$104K	0.27%	17
2024 Q3	$5.81M	Hold	69,310	–	–	0.25%	18
2024 Q2	$4.76M	Hold	69,310	–	–	0.21%	18
2024 Q1	$5.08M	Hold	69,310	–	–	0.23%	18
2023 Q4	$5.61M	Hold	69,310	–	–	0.28%	17
2023 Q3	$5.19M	Hold	69,310	–	–	0.29%	18
2023 Q2	$5.34M	Sell	69,310 -804	-1%	-$64.1K	0.29%	17
2023 Q1	$5.82M	Hold	70,114	–	–	0.33%	17
2022 Q4	$6.02M	Hold	70,114	–	–	0.38%	16
2022 Q3	$4.33M	Hold	70,114	–	–	0.28%	18
2022 Q2	$4.33M	Hold	70,114	–	–	0.26%	17
2022 Q1	$4.17M	Hold	70,114	–	–	0.2%	18
2021 Q4	$5.09M	Hold	70,114	–	–	0.22%	18
2021 Q3	$4.9M	Buy	70,114 +140	+0.2%	+$9.84K	0.24%	18
2021 Q2	$4.82M	Hold	69,974	–	–	0.24%	18
2021 Q1	$4.52M	Buy	69,974 +94	+0.1%	+$6.06K	0.25%	18
2020 Q4	$4.07M	Hold	69,880	–	–	0.24%	18
2020 Q3	$4.42M	Hold	69,880	–	–	0.3%	17
2020 Q2	$5.38M	Hold	69,880	–	–	0.39%	16
2020 Q1	$5.22M	Hold	69,880	–	–	0.42%	18
2019 Q4	$4.54M	Hold	69,880	–	–	0.3%	24
2019 Q3	$4.43M	Hold	69,880	–	–	0.31%	22
2019 Q2	$4.72M	Sell	69,880 -100	-0.1%	-$6.58K	0.32%	23
2019 Q1	$4.55M	Buy	69,980 +100	+0.1%	+$6.65K	0.33%	24
2018 Q4	$4.37M	Hold	69,880	–	–	0.36%	23
2018 Q3	$5.39M	Hold	69,880	–	–	0.38%	25
2018 Q2	$4.95M	Hold	69,880	–	–	0.38%	24
2018 Q1	$5.27M	Hold	69,880	–	–	0.43%	23
2017 Q4	$5.01M	Hold	69,880	–	–	0.41%	24
2017 Q3	$5.66M	Hold	69,880	–	–	0.51%	21
2017 Q2	$4.95M	Sell	69,880 -8,760	-11%	-$583K	0.45%	22
2017 Q1	$5.34M	Sell	78,640 -5,116	-6%	-$360K	0.51%	23
2016 Q4	$6M	Hold	83,756	–	–	0.62%	21
2016 Q3	$6.63M	Hold	83,756	–	–	0.59%	20
2016 Q2	$6.99M	Sell	83,756 -2,500	-3%	-$222K	0.64%	20
2016 Q1	$7.92M	Sell	86,256 -679	-0.8%	-$61.2K	0.72%	20
2015 Q4	$8.8M	Buy	86,935 +280	+0.3%	+$29.1K	0.47%	30
2015 Q3	$8.51M	Buy	86,655 +299	+0.3%	+$33.2K	0.44%	32
2015 Q2	$10.1M	Hold	86,356	–	–	0.5%	27
2015 Q1	$8.47M	Sell	86,356 -400	-0.5%	-$40.6K	0.4%	30
2014 Q4	$8.18M	Hold	86,756	–	–	0.38%	30
2014 Q3	$9.23M	Hold	86,756	–	–	0.52%	25
2014 Q2	$7.19M	Hold	86,756	–	–	0.39%	25
2014 Q1	$6.15M	Hold	86,756	–	–	0.34%	26
2013 Q4	$6.51M	Hold	86,756	–	–	0.36%	28
2013 Q3	$5.45M	Buy	86,756 +32,100	+59%	+$1.92M	0.32%	29
2013 Q2	$2.8M	Buy	+54,656	New	+$2.85M	0.17%	40

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital Counsel's GILD Position: Q1 2026 in Review

Capital Counsel reduced its Gilead Sciences (GILD) stake by 0.41% in Q1 2026, selling an estimated $39.5K and leaving 68,928 shares worth $9.61M. The position accounts for 0.41% of the portfolio, ranked #17.

Capital Counsel first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.1M in Q2 2015. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Capital Counsel held 68,928 shares of Gilead Sciences worth $9.61M as of Q1 2026.
Capital Counsel sold 282 Gilead Sciences shares in Q1 2026, an estimated $39.5K.
Gilead Sciences made up 0.41% of Capital Counsel's portfolio in Q1 2026, its #17 holding.
Capital Counsel first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
Capital Counsel's Gilead Sciences position peaked at $10.1M in Q2 2015.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Capital Counsel's 13F filing for Q1 2026, filed 15 May 2026.